معرفی
Dr. Angela DeMichele is a Professor at the University of Pennsylvania holding the Mariann T. and Robert J. MacDonald Professorship in Breast Cancer Care Excellence. She serves as Co-Leader of the Breast Cancer Research Program and Co-Director of the 2-PREVENT Breast Cancer Translational Center of Excellence at Penn Medicine's Abramson Cancer Center, with clinical practice at the Rena Rowan Breast Center and hospital privileges at the Hospital of the University of Pennsylvania.
Her educational background includes:
- Medical School: Washington University in St. Louis
- Residency: Hospital of the University of Pennsylvania
- Fellowship: University of Bologna School of Medicine
- Fellowship: Hospital of the University of Pennsylvania
Dr. DeMichele's research focuses on pioneering breast cancer therapies through neoadjuvant treatment optimization and recurrence prevention strategies. Her translational approach integrates clinical trial data with biomarker discovery to personalize therapeutic interventions, particularly for HER2-positive and hormone receptor-positive subtypes. This work directly informs clinical practice through national consortia leadership.
Analysis of her 2025 publications reveals dominant trends in immunotherapy response prediction (using immune subtyping), surgical timing impacts, and CDK4/6 inhibitor mechanisms. Her research consistently leverages the I-SPY2 platform for adaptive trial design, with growing emphasis on health equity through disparity analyses in axillary management.
Her national leadership roles demonstrate significant professional recognition:
- Co-Chair, ECOG/ACRIN Cooperative Group Breast Committee
- Chair, Trial Operations Working Group, I-SPY Consortium
- Member, NCI Breast Cancer Steering Committee
Dr. DeMichele maintains active clinical practice with exceptional patient satisfaction (5.0/5.0 from 252 reviews), balancing translational research with direct patient care. Her mentorship extends through collaborative trial networks rather than formal student advisement.
She leads the 2-PREVENT Breast Cancer Translational Center of Excellence which focuses on translating dormancy biology into clinical strategies for preventing recurrence, representing a unique niche in breast cancer research infrastructure.
